CASI Pharmaceuticals Inc (CASI) – Company Profile and SWOT Analysis

CASI Pharmaceuticals Inc (CASI) – Company Profile & SWOT Analysis, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company.

Key Highlights

CASI Pharmaceuticals Inc (CASI) is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapies for treating cancer and other unmet medical needs. The company’s product EVOMELA (melphalan for injection) an intravenous formulation for the treatment of multiple myeloma. It’s pipeline product portfolio includes CID-103 for the treatment of multiple myeloma; CNTC-19 for hematological malignancies; BI-1206 for non-Hodgkin’s lymphoma and solid tumors; CB-5339 AML/MDS and solid tumors; Octreotide LAI for the treatment of acromegaly and symptoms associated with neuroendocrine tumors. It works with Spectrum Pharmaceuticals Inc, Acrotech, and Juventas Cell Therapy, among others, to develop and distribute its products. The company operates its subsidiaries in the US and China and a research and development center in Beijing, China. CASI is headquartered in Beijing, China.

Scope

Detailed information on CASI Pharmaceuticals Inc required for business and competitor intelligence needs

A study of the major internal and external factors affecting CASI Pharmaceuticals Inc in the form of a SWOT analysis

An in-depth view of the business model of CASI Pharmaceuticals Inc including a breakdown and examination of key business segments

News about CASI Pharmaceuticals Inc, such as business expansion, restructuring, and contract wins

Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

Gain understanding of CASI Pharmaceuticals Inc and the factors that influence its strategies.

Track strategic initiatives of the company and latest corporate news and actions.

Assess CASI Pharmaceuticals Inc as a prospective partner, vendor or supplier.

Support sales activities by understanding your customers' businesses better.

Stay up to date on CASI Pharmaceuticals Incs business structure, strategy and prospects.

Note: Some sections may be missing if data is unavailable for the company.

Companies mentioned

Cardiff Oncology Inc

Viva Biotech Holdings

Shanghai GeneChem Co Ltd

Hualan Biological Engineering Inc

Genentech USA Inc

Fennec Pharmaceuticals Inc

Zivo Bioscience Inc

Natsar Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1 - About the Company

CASI Pharmaceuticals Inc - Key Facts

CASI Pharmaceuticals Inc - Key Employees

CASI Pharmaceuticals Inc - Key Employee Biographies

CASI Pharmaceuticals Inc - Major Products and Services

CASI Pharmaceuticals Inc - History

CASI Pharmaceuticals Inc - Company Statement

CASI Pharmaceuticals Inc - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2 – Company Analysis

Company Overview

CASI Pharmaceuticals Inc - Business Description

R&D Overview

CASI Pharmaceuticals Inc - Corporate Strategy

CASI Pharmaceuticals Inc - SWOT Analysis

SWOT Analysis - Overview

CASI Pharmaceuticals Inc - Strengths

CASI Pharmaceuticals Inc - Weaknesses

CASI Pharmaceuticals Inc - Opportunities

CASI Pharmaceuticals Inc - Threats

CASI Pharmaceuticals Inc - Key Competitors

Section 3 – Company Financial Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 – Company’s Lifesciences Financial Deals and Alliances

CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025

CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025

CASI Pharmaceuticals Inc, Recent Deals Summary

Section 5 – Company’s Recent Developments

Mar 31, 2025: CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Business and Financial Results

Nov 15, 2024: CASI Pharmaceuticals Reports Q3 2024 Business and Financial Results

Aug 16, 2024: CASI Pharmaceuticals Reports Q2 2024 Results

Apr 08, 2024: CASI Pharmaceuticals Reports Development Relating to Its Disputes With Juventas

Mar 28, 2024: CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTS

Section 6 – Appendix

Methodology

Ratio Definitions

About MarketLine

Contact Us

Disclaimer

List of Tables

List of Tables

CASI Pharmaceuticals Inc, Key Facts

CASI Pharmaceuticals Inc, Key Employees

CASI Pharmaceuticals Inc, Key Employee Biographies

CASI Pharmaceuticals Inc, Major Products and Services

CASI Pharmaceuticals Inc, History

CASI Pharmaceuticals Inc, Other Locations

CASI Pharmaceuticals Inc, Subsidiaries

CASI Pharmaceuticals Inc, Key Competitors

CASI Pharmaceuticals Inc, Annual Ratios

CASI Pharmaceuticals Inc, Annual Ratios (Cont…1)

CASI Pharmaceuticals Inc, Annual Ratios (Cont…2)

CASI Pharmaceuticals Inc, Interim Ratios

CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025

CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025

CASI Pharmaceuticals Inc, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

List of Figures

List of Figures

CASI Pharmaceuticals Inc, Performance Chart (2020 – 2024)

CASI Pharmaceuticals Inc, Ratio Charts

CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025

CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2019 to YTD 2025

    Pricing

Discounts available for multiple purchases.

reportstore@marketline.com
+44 20 7947 2960

Saved reports